← Back to Patent Explorer
EP0224151A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

2-Substituted-[2-substituted-amino]-N-aralkyl-3-[indol-3-yl]propanamides

Assignee: Warner Lambert Co LLC
•
Filing: 1986-11-14
•
Granted: —
•
Expires: 2006-11-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Certain 2-substituted-[2-substituted-aminol-N-arylalkyl-3-[indo]-3-yl]propanamides demonstrate activity as appetite suppressants. The compounds, pharmaceutical compositions, and a method of suppressing appetite are disclosed.

Inventors

  • 👤 David C. Horwell

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-27 17:05
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; C07D209/00; C07D209/02; C07D209/04; C07D209/10; C07D209/18; C07D209/20; C07D405/00; C07D405/02; C07D405/12; C07D409/00; C07D409/02; C07D409/12; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06139; C07K5/06156

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 276 words
BE, CH, DE, FR, GB, IT, LI, LU, NL, SE ) 1. A compound having structural formula 1: wherein A is -NH-, or -(CH2)n, where n is an integer of from zero to six; R 1 is an N-terminal blocking group selected from and R 2 and R 3 are independently hydrogen, straight or branched alkyl of from one to six carbon atoms, trifluoromethyl, -CH 2 -CH=CH 2 , -CH 2 -C≡CH, -CH 2 0R, -(CH 2 ) m COOR, -(CH 2 ) m NR 6 R 7 , -CH 2 Ar or -CH 2 OAr, where m is an integer of from one to six, R, R 6 , and R 7 are selected from hydrogen, or straight or branched alkyl of from one to six carbon atoms, and Ar is 2-, or 3-thienyl, 2-, 3-, or 4-pyridinyl, or where X and Y are independently hydrogen, fluorine, chlorine, methyl, methoxyl, trifluoromethyl, or nitro, with the provisos that when X is nitro, Y is hydrogen, and R 2 and R 3 may not both be hydrogen, R 4 is hydrogen, -CH 2 OH, -CONR 6 R 7 , -CH 2 NR 6 R 7 , -COOR or where Z is -CH 2 -, >NR, oxygen, or sulfur, and R, R 6 , and R 7 are as previously defined, and R 5 is 2- or 3-thienyl, 2-, 3-, or 4-pyridinyl, 2- or 3-indanyl, cyclohexyl, 2- or 3-furanyl, 3- or 4-pyridazinyl, 2-imidazolyl, 2-benzimidazolyl, 2-tetrahydrobenzimidazolyl, 2-perimidyl, or where X and Y are independently hydrogen, fluorine, chlorine, methyl, methoxyl, trifluoromethyl, or nitro, with the proviso that when X is nitro, Y is hydrogen, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim 82 words
A compound as defined by Claim 1 wherein R 2 is hydrogen, methyl or trifluoromethyl; R 4 is hydrogen, hydroxymethyl, or -CONH 2 ; R 5 isphenyl, 2-, 3-, or 4-pyridinyl, 2- or 3-thienyl, 2- or 3-indanyl, 2- or 3-furanyl, 3- or 4-pyridazinyl, 2-imidazolyl, 2-benzimidazolyl, 2-tetrahydrobenzimidazolyl, 2-perimidyl, cyclohexyl or where X and Y are independently hydrogen, fluorine, chlorine, methyl, methoxyl, trifluoromethyl, or nitro, with the proviso that when X is nitro, Y is hydrogen as well as the pharmaceutical acceptable salts thereof.
Claim 3
Dependent Claim 12 words
A compound as defined by Claim 1 having the name N-[(1,1-dimethylethoxy)carbonyl]-α-DL-methyl- tryptophyl-L-phenylalaninamide.
Claim 4
Dependent Claim 14 words
A compound as defined by Claim 1 having the name [1-(1H-indole-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamic acid, 1,1-dimethylpropyl ester.
Claim 5
Dependent Claim 16 words
5 , A compound as defined by Claim 1 having the name [2-[[1-(hydroxymethyl)-2-phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamic acid, 1,1-dimethylpropyl ester.
Claim 6
Dependent Claim 29 words
A pharmaceutical composition comprising an amount of a compound as defined by Claim 1 effective to suppress the food intake of a mammal together with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim 113 words
A process for preparing a compound having the structural formula 1 wherein A, R 1 R 2 , R 3 , R 4 , and R 5 have the meaning given in Claim 1 or a pharmaceutically acceptable salt thereof comprising the step of condensing an N-terminus-blocked amino acid having the structural formula 2 where R 1 and R 2 are as defined above, with an amine having the structure where R 3 , R 4 , and R 5 are as defined above in the presence of dicyclohexylcarbodiimide or carbonyldiimidazole in an inert solvent, and thereafter, converting the product of said condensation to a pharmaceutically acceptable salt, if desired, by conventional means.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag